US FDA’s Real-Time Oncology Review Program Is No Guarantee For Early Approval

 
• By Sue Sutter and Bridget Silverman
Early start
Under RTOR, FDA can get an early jump on reviewing a drug's efficacy and safety data. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards